华人健康
(301408)
| 流通市值：18.68亿 | | | 总市值：50.08亿 |
| 流通股本：1.49亿 | | | 总股本：4.00亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,104,366,687.97 | 3,797,160,297.68 | 2,678,296,897.28 | 1,730,970,743.87 |
| 营业收入 | 1,104,366,687.97 | 3,797,160,297.68 | 2,678,296,897.28 | 1,730,970,743.87 |
| 利息收入 | - | - | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 1,032,719,031.44 | 3,656,977,275.19 | 2,573,336,182.13 | 1,661,496,493.18 |
| 营业成本 | 741,621,514.46 | 2,633,730,658.54 | 1,832,716,334.18 | 1,186,235,085.86 |
| 利息支出 | 0 | 0 | 0 | - |
| 手续费及佣金支出 | 0 | 0 | 0 | - |
| 退保金 | 0 | 0 | 0 | - |
| 赔付支出净额 | 0 | 0 | 0 | - |
| 提取保险合同准备金净额 | 0 | 0 | - | - |
| 保单红利支出 | 0 | 0 | 0 | - |
| 分保费用 | 0 | 0 | 0 | - |
| 税金及附加 | 4,984,516.12 | 16,717,939.16 | 10,549,548.41 | 6,193,795.98 |
| 销售费用 | 229,475,919.98 | 804,473,521.27 | 592,821,644.44 | 380,607,113.78 |
| 管理费用 | 45,542,950.9 | 158,510,878.46 | 114,829,722.75 | 76,117,000.09 |
| 研发费用 | 6,196,651.12 | 24,194,023.68 | 8,848,463.74 | 4,329,232.28 |
| 财务费用 | 4,897,478.86 | 19,350,254.08 | 13,570,468.61 | 8,014,265.19 |
| 其中:利息费用 | 4,245,297.67 | 12,242,661.36 | 7,031,581.04 | 0 |
| 其中:利息收入 | 4,626,783.53 | 14,066,684.55 | 7,883,960.7 | 0 |
| 加:公允价值变动收益 | 13,770.24 | 33,945.6 | 32,427.95 | 0 |
| 加:投资收益 | 246,761.45 | 770,340.21 | 422,666.24 | 164,442.42 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 637,289.25 | 1,044,827.91 | 279,617.74 | 127,694.74 |
| 资产减值损失(新) | -1,606,455.64 | -6,864,244.99 | -3,701,109.69 | -3,862,954.26 |
| 信用减值损失(新) | -4,866,976.71 | -4,589,274.45 | -2,614,011.89 | -2,870,790.22 |
| 其他收益 | 3,329,428 | 22,144,774.67 | 18,902,747.62 | 14,663,180.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 69,401,473.12 | 152,723,391.44 | 118,283,053.12 | 77,695,823.63 |
| 加:营业外收入 | 158,443.77 | 230,367.02 | 210,096.72 | 164,642.08 |
| 减:营业外支出 | 375,945.72 | 1,445,892.61 | 552,145.35 | 269,080.43 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 69,183,971.17 | 151,507,865.85 | 117,941,004.49 | 77,591,385.28 |
| 减:所得税费用 | 16,683,609.08 | 33,825,557.68 | 29,309,613.08 | 19,588,816.54 |
| 六、净利润 | 52,500,362.09 | 117,682,308.17 | 88,631,391.41 | 58,002,568.74 |
| 持续经营净利润 | 52,500,362.09 | 117,682,308.17 | 88,631,391.41 | 58,002,568.74 |
| 终止经营净利润 | 0 | - | 0 | - |
| 归属于母公司股东的净利润 | 47,772,301.04 | 114,667,584.92 | 88,017,299.03 | 58,242,613.72 |
| 少数股东损益 | 4,728,061.05 | 3,014,723.25 | 614,092.38 | -240,044.98 |
| (一)基本每股收益 | 0.12 | 0.29 | 0.23 | 0.15 |
| (二)稀释每股收益 | 0.12 | 0.29 | 0.23 | 0.15 |
| 八、其他综合收益 | 0 | 2,134,785.55 | 2,134,785.55 | 2,134,785.55 |
| 归属于母公司股东的其他综合收益 | 0 | 2,134,785.55 | 2,134,785.55 | 2,134,785.55 |
| 九、综合收益总额 | 52,500,362.09 | 119,817,093.72 | 90,766,176.96 | 60,137,354.29 |
| 归属于母公司股东的综合收益总额 | 47,772,301.04 | 116,802,370.47 | 90,152,084.58 | 60,377,399.27 |
| 归属于少数股东的综合收益总额 | 4,728,061.05 | 3,014,723.25 | 614,092.38 | -240,044.98 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-28 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |